A Randomized Study of INC424 (INCB018424) Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

Trial Profile

A Randomized Study of INC424 (INCB018424) Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms COMFORT-II
  • Sponsors Incyte Corporation; Novartis
  • Most Recent Events

    • 06 Dec 2016 Results of polled overall analysis of 5 year data (n=528) from NCT00952289 and NCT00934544 trials presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Pooled analysis results (n=301) from COMFORT-I and -II trial presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2016 Results of an exploratory pooled analysis from COMFORT-I & COMFORT-II trials published in an Incyte Corporation Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top